(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 648.8MM | +0% |
Gross Profit | 523.7MM | - |
Cost Of Revenue | 125.2MM | -1% |
Operating Income | 88.5MM | - |
Operating Expenses | 435.2MM | - |
Net Income | 88.7MM | - |
R&D | 205MM | -1% |
G&A | 225.9MM | -21% |
Interest Expense | 3.5MM | -42% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its first-quarter result to...
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Insightful Analysis of Biomarin Pharmaceutical Inc's Strengths, Weaknesses, Opportunities, and Threats
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript April 24, 2024 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.71, expectations were $0.6. BioMarin Pharmaceutical Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name […]
BioMarin Pharmaceutical ( NASDAQ:BMRN ) First Quarter 2024 Results Key Financial Results Revenue: US$648.8m (up 8.8...
The Food and Drug Administration approval of Beqvez comes as other gene therapies for the bleeding condition struggle to gain traction.
BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
Q1 2024 Biomarin Pharmaceutical Inc Earnings Call